RxDoctor Payments Data

Tania Babar, MD

Clinical Cardiac Electrophysiology · Charleston, WVNPI 1598939027

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (35.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Medtronic at 53.4% of the total.

$28,842in general payments, 2019–2025

Across 273 payments — averaging $105.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Boston Scientific$6K
  • Abbott$3K
  • Biosense Webster, Inc.$2K
  • Kestra Medical Technology Services, Inc.$1K
  • Biotronik Inc.$778
  • plus $714 from 5 others

What the payments were for

  • Consulting fees$9,45033%
  • Travel & lodging$10,13535%
  • Food & beverage$9,25832%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$165,075
Medicare patients
1,981
Services billed
3,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$135,141
XareltoRivaroxaban18$26,457
Metoprolol Succinate124$2,193
Dofetilide21$2,075
Amiodarone Hcl88$1,020
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$546
Sucralfate36$207
Omeprazole36$185
Metoprolol Tartrate31$168
Mupirocin23$161
SotalolSotalol Hcl13$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$22$26,45718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →